Pulmobiotics Overview

  • Year Founded
  • 2020

Year Founded

  • Status
  • Private

  • Employees
  • 7

Employees

  • Latest Deal Type
  • Seed

  • Latest Deal Amount
  • $2.21M

  • Investors
  • 1

Pulmobiotics General Information

Description

Developer of novel antigens and vaccines intended to cure human lung illnesses. The company's attenuated lung bacteria are able to expose antigens or deliver therapeutic agents in the lung in a controlled, local and continuous manner to specifically target and deliver payloads, enabling patients to heal their breathing-related problems.

Contact Information

Website
www.pulmobio.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Passeig de Gràcia
  • Number 54, 02 D
  • 08007 Barcelona
  • Spain
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Vertical(s)
Life Sciences
Corporate Office
  • Passeig de Gràcia
  • Number 54, 02 D
  • 08007 Barcelona
  • Spain

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Pulmobiotics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Seed Round 26-Mar-2020 $2.21M Completed Startup
To view Pulmobiotics’s complete valuation and funding history, request access »

Pulmobiotics Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Ordinary
To view Pulmobiotics’s complete cap table history, request access »

Pulmobiotics Patents

  • 3

    Total Documents Applications and Grants

  • Total Patents Families

  • Granted

  • 3

    Pending

  • Expiring in next 12 mo

Pulmobiotics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4479530-A1 Systems, tools, and methods for engineering bacteria Pending 18-Feb-2022
EP-4405488-A1 Genetically modified mycoplasma bacteria active against heterogenous bacterial biofilms Pending 20-Sep-2021
US-20240382537-A1 Genetically modified mycoplasma bacteria active against heterogenous bacterial biofilms Pending 20-Sep-2021 A61K35/74

Pulmobiotics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Pulmobiotics Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds
Invivo Partners Venture Capital Minority
To view Pulmobiotics’s complete investors history, request access »

Ready to get started?

Request a free trial

Pulmobiotics FAQs

  • When was Pulmobiotics founded?

    Pulmobiotics was founded in 2020.

  • Where is Pulmobiotics headquartered?

    Pulmobiotics is headquartered in Barcelona, Spain.

  • What is the size of Pulmobiotics?

    Pulmobiotics has 7 total employees.

  • What industry is Pulmobiotics in?

    Pulmobiotics’s primary industry is Biotechnology.

  • Is Pulmobiotics a private or public company?

    Pulmobiotics is a Private company.

  • What is the current valuation of Pulmobiotics?

    The current valuation of Pulmobiotics is .

  • What is Pulmobiotics’s current revenue?

    The current revenue for Pulmobiotics is .

  • How much funding has Pulmobiotics raised over time?

    Pulmobiotics has raised $2.21M.

  • Who are Pulmobiotics’s investors?

    Invivo Partners has invested in Pulmobiotics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »